We need the people's prescription to fix pharma


19 October 2018

Share this graphic on Facebook or Twitter 

Last year we released a report exposing pharmaceutical companies ripping-off patients through high-priced medicines. We toured the country and spoke to members of the public about the problem of putting profit above patient needs. And we heard one resounding question - what are the alternatives to this system? 

Over the last few months we’ve been working with author and economist, Mariana Mazzucato and her team at the UCL Institute for Innovation and Public Purpose along with our campaigning allies, STOPAIDS and Just Treatment to answer that question. 

With the help of our supporters and members we’ve been able to produce a new report. ‘The people’s prescription: Re-imagining health innovation to deliver public value’ reveals how pharmaceutical companies not only charge unaffordable prices for medicines, they are also not delivering the drugs we need. It’s a scandal of our time but there are alternatives to a system that puts profits above public need. 

The report has already made a splash in the media. It was in The TimesWashington Post, and BBC Radio 4’s Today Programme, just to name a few. We also celebrated with a launch event. With speakers from the likes of the World Health Organisation, it was encouraging to hear that our report is being discussed on these platforms.

Share this graphic on Facebook or Twitter

Our report sheds light on alternatives that put public health needs, not profits, at the forefront of drug research and development.

An immediate step governments can do right now is to use their legal rights to override drug monopolies to enable lower drug prices.

However in the long term, we need more transformative proposals including:   

  • Changing the incentives in the system. Right now, big pharma is incentivised by high prices to develop new drugs. We could reward innovators with an upfront prize and then allow different producers to compete to make the drug.
  • Public funding for research and development should include conditions to ensure that drugs produced from public research is both accessible and affordable.

The corporate grip of medicines is failing patients here in the UK and across the world. For people’s health, for their lives, it’s time for change and real alternatives.

 

Blog

The government’s trade agenda threatens disastrous deregulation – but we can stop it


15 January 2021

The Brexit trade deal with the EU might be completed, but the type of country Britain becomes next is still to be defined - and trade rules will play a key role in shaping our future. That’s why we need to keep campaigning on trade in the months and years ahead.  

What we've stood for together in 2020


21 December 2020

We have lived through 12 months dominated by coronavirus – a disease which has exposed the fragility and inequality of the global economy like nothing before. This virus has turned our world upside down, and we want to offer our heartfelt thanks for your support in such a difficult time. 

Three things I don’t want to find in my Christmas stocking


19 December 2020

Why we need to stop a US-UK trade deal if we don't wanted banned chemicals in our Christmas presents.

Related content